Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Jounce Therapeutics, Inc. (JNCE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/15/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 05/05/2023 |
4
| Concentra Biosciences, LLC (10% Owner) has filed a Form 4 on Jounce Therapeutics, Inc.|
Txns:
| Acquired 10,000 shares
@ $9737.7, valued at
$97.4M
|
|
| 05/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/05/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 05/05/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/05/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/05/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/04/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2023 |
4
| Kamen Robert (Director) has filed a Form 4 on Jounce Therapeutics, Inc.|
Txns:
| Unknown transaction of 60,975 shares
@ $0
Unknown transaction of 33,875 shares
@ $0
Disposed/sold 10,840 options to buy
@ $9.56, valued at
$103.6k
Disposed/sold 13,550 options to buy
@ $7.92, valued at
$107.3k
Disposed/sold 15,700 options to buy
@ $4.46, valued at
$70k
Disposed/sold 15,700 options to buy
@ $7.58, valued at
$119k
Disposed/sold 15,700 options to buy
@ $7.27, valued at
$114.1k
Disposed/sold 20,000 options to buy
@ $2.8, valued at
$56k
|
|
| 05/04/2023 |
4
| Iannone Robert (Director) has filed a Form 4 on Jounce Therapeutics, Inc.|
Txns:
| Disposed/sold 31,400 options to buy
@ $7.19, valued at
$225.8k
Disposed/sold 7,850 options to buy
@ $7.58, valued at
$59.5k
Disposed/sold 15,700 options to buy
@ $7.27, valued at
$114.1k
Disposed/sold 20,000 options to buy
@ $2.8, valued at
$56k
|
|
| 05/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2023 |
4
| Diaz Luis (Director) has filed a Form 4 on Jounce Therapeutics, Inc.|
Txns:
| Disposed/sold 27,100 options to buy
@ $14.78, valued at
$400.5k
Disposed/sold 10,163 options to buy
@ $7.92, valued at
$80.5k
Disposed/sold 15,700 options to buy
@ $4.46, valued at
$70k
Disposed/sold 15,700 options to buy
@ $7.58, valued at
$119k
Disposed/sold 15,700 options to buy
@ $7.27, valued at
$114.1k
Disposed/sold 20,000 options to buy
@ $2.8, valued at
$56k
|
|
| 05/04/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/04/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/04/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/04/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/04/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/04/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/04/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/04/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/04/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 05/04/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 04/28/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 04/25/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 04/24/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 04/06/2023 |
4
| MURRAY RICHARD /CA/ (Director) has filed a Form 4 on Jounce Therapeutics, Inc.|
Txns:
| Sold 39,228 shares
@ $1.85, valued at
$72.6k
|
|
| 04/06/2023 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
|
|
|